Clinical profile, treatment, and visual outcome of ampiginous choroiditis.
OBJECTIVE
To report the clinical profile and management of patients diagnosed to have ampiginous choroiditis in a tertiary care referral centre in India.


METHODS
Retrospective cohort study. Twenty-six eyes of 16 patients were included in the study, which was diagnosed as choroiditis, serpiginous choroiditis, and acute posterior multifocal placoid pigment epitheliopathy (APMPPE) or ampiginous choroiditis. Those who were initially diagnosed as having other forms of choroiditis were later classified as having ampiginous choroiditis clinically. Systemic steroids and immunosuppressives were the mainstay of therapy.


RESULTS
There was a male preponderance (7:3). Age at presentation ranged from 22 years to 57 years with a (median 34 years); 81% had bilateral involvement and 35% had recurrences. Vision improved or maintained in 24 eyes, whereas it deteriorated in 2 eyes due to subretinal fibrosis and macula involvement, respectively. Resolution of lesions and improvement or stability of vision can occur with administration of timely steroids and immunosuppressive therapy. Regular follow-up is necessary to monitor the disease progression, recurrences, and involvement of the other eye.


CONCLUSIONS
Ampiginous choroiditis is a separate disease entity due to its distinct clinical features. It is a disease with multiple relapses, which can be effectively controlled with a combination of immunosuppressive therapy, and a good visual acuity can be maintained on long-term follow-up.
Jyotirmay
Biswas
B
Jafferji
Shafiq S
SS
Sudharshan
Sridharan
S
Kalpana
Badami
B
D000328:Adult; D002825:Chorioretinitis / Q000175:diagnosis / Q000188:drug therapy / Q000473:pathology; D002833:Choroiditis / Q000175:diagnosis* / Q000188:drug therapy* / Q000473:pathology; D015331:Cohort Studies; D016572:Cyclosporine / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D007194:India; D008297:Male; D015122:Mercaptopurine / Q000031:analogs & derivatives / Q000627:therapeutic use; D008875:Middle Aged; D011239:Prednisolone / Q000627:therapeutic use; D012189:Retrospective Studies; D016896:Treatment Outcome; D014792:Visual Acuity / Q000187:drug effects
D007166:Immunosuppressive Agents; C488629:azathiopurine; D016572:Cyclosporine; D011239:Prednisolone; D015122:Mercaptopurine